Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Polaryx Therapeutics has appointed Dr. Will Charlton as Chief Medical Officer to strengthen clinical leadership ahead of its Phase 2 SOTERIA trial initiation in Q4 2026. Dr. Charlton brings extensive rare disease and pediatric drug development experience, which is expected to enhance execution capabilities for the company's lead candidate, PLX-200,…